Skip to main content

Immune Response BioPharma, Inc.

Home
Drug Discovery
Press Releases
Investor Relations
Royalties
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNE Rx Co-pay Card
REMUNE FULL PRESCRIBING
REMUNEX Vaccine
Remune Pediatric
RemuneVax Vaccine
NeuroVax Vaccine
NeurOral
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
DermaVax
Immunereszumab
Sepsicillin
Rare Diseases
Alliances
Vaccines Direct
Partnering
Bio Defense
Immune Response Hospital
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Employment
Events
Webcast
Contact Us
Email Alerts
Member Login
Site Map
Immune Response BioPharma, Inc. TM

Alliances:       © 2010-2018
undefined
By partnering out manufacturing and drug development the company intends to become a royalty generating income producing company.
 
 
Patent Coverage through 2027 with U.S. Patent 8,053,197 Issued & Granted Ownership to Immune Response BioPharma, Inc. for Auto-Immune Diseases Proprietary FOXP3+ Expression Technology
 
 
Website is Powered by Microsoft
 
 
Web Properties owned www.remune.org  www.NeuroVax.net & www.Sepsicillin.com www.orchestratherapeutics.net www.immuneresponse.net 
 
Licensing
 
 
Immune Response BioPharma, Inc. has Ownership of U.S. Patent 8,053,197 to IRBP for Auto-Immune Diseases Proprietary FOXP3+ Expression Technology Extends IP Coverage Through 2027




Pipeline Manufacturing Partners:





Industry Links:  



undefined



Immune Response BioPharma, Inc. TM 
 All Rights Reserved 

Collaborations & Manufacturing Partners

 

 

OHSU Oregon Health & Science University

www.ohsu.edu/neurology

 

 

 

 

 Pipeline Manufacturing Partners 

 

 

 

  









Copyright © 2010-2018   www.immuneresponse.net